3D-FibroScreen is advancing first-in-class therapies that target the root causes of tissue fibrosis, aiming to improve quality of life for patients with fibrotic diseases. The company focuses on translating research breakthroughs into impactful treatments, building on a foundation of drug development expertise and a specialized pharmaceutical screening platform.
Funding
Funding not disclosed
Founders
Product
Problem
Tissue fibrosis, characterized by excessive scar tissue formation, underlies numerous chronic and life-threatening diseases with limited treatment options. Existing therapies often manage symptoms rather than addressing the underlying biological drivers, leaving patients with progressive organ damage and reduced quality of life.
Solution
3D-FibroScreen develops first-in-class therapies that directly target the root causes of tissue fibrosis, offering a disease-modifying approach rather than symptomatic relief. The company leverages a cutting-edge pharmaceutical screening platform to identify and validate therapeutic candidates with high precision, accelerating the path from research discovery to clinical application. By focusing on the mechanisms driving fibrosis, the company aims to halt or reverse disease progression and deliver meaningful improvements in patient outcomes.
Target Audience
Primary customers are patients with fibrotic diseases and the healthcare providers who treat them, as well as biopharmaceutical partners seeking innovative therapies for this underserved condition.
Features
- Targets root-cause biological pathways involved in fibrotic tissue formation
- Utilizes a cutting-edge pharmaceutical screening platform for drug discovery and validation
- Focuses on first-in-class therapeutic candidates for differentiated treatment options
- Pipeline oriented toward clinical-stage development and regulatory approval
- Aims to address multiple fibrotic disease indications with high unmet medical need